Status message

Not the entire site translated, but only to "Journal"

On the subject of combination therapy of schizophrenia

Petrova N. N.
Saint-Petersburg State University, department of psychiatry and narcology, Saint-Petersburg, Russia
SUMMARY:
The review article describes the antipsychotic polytherapy of schizophrenia at the present stage, provides data on its prevalence and possible causes. A comparative assessment of combined antipsychotic therapy and monotherapy for schizophrenia is given. The features of combined antipsychotic therapy using injectable prolonged second-generation antipsychotics are described.
CONTACT: petrova_nn@mail.ru

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Tebeka S., Airagnes G., Limosin F. When and how prescribe antipsychotics? [Article in French] // Rev Med Interne. – 2017. – Vol. 38, No. 5. – R. 328–336. – DOI: 10.1016/j.revmed.2016.12.007
2.    National Collaborating Center for Mental Health (UK). Psychosis and Schizophrenia in Adults. – London, United Kingdom: National Institute for Health and Care Excellence (UK), 2014.
3.    Huhn M., Nikolakopoulou A., Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis // Lancet. –2019. – Vol. 394. – R. 939–951.
4.    Kahn R.S., Sommer I.E., Murray R.M. et al. Schizophrenia // Nat Rev Dis Primers. – 2015. No. 1. – R. 15067. – DOI: 10.1038/nrdp.2015.67
5.    Tiihonen J., Tanskanen A., Taipale H. 20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia // Am J Psychiatry. – 2018. – Vol. 175. – R. 765–773.
6.    Petrova N.N., Serazetdinova L.G., Baranov S.N., Vishnevskaya O.A., Malevanaya O.V., Moskovtseva O.R. Kseplion v reshenii aktual'nykh problem lecheniya bol'nykh shizofreniei // Sotsial'naya i klinicheskaya psikhiatriya. – 2013. – T. 23, vyp. 1. – S. 85–90. 
7.    Park S-C., Choi M.Y., Choi J. et al. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: A systematic review and meta-analysis // Clinical Psychopharmacology and Neuroscience. – 2018. – Vol. 16, No. 4. – R. 361–375. – DOI: 10.9758/cpn.2018.16.1.361
8.    Salgueiro M., Segarra R. Long-acting injectable second generation antipsychotics in first episode psychosis: a narrative review // International Clinical Psychopharmacology. –2019. – Vol. 34, No. 2. – R. 51–56. – DOI: 10.1097/YIC.0000000000000249
9.    Schreiner A., Bergmans R., Cherubin R. Et al. A Prospective flexible-dose study of Paliperidone Palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents // Clinical Therapeutics. – 2014. – Vol. 36, No. 10. – R. 1372-88.e1. – DOI: 10.1016/j.clinthera.2014.08.014
10.    Barnes T.R., Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks // CNS Drugs. – 2011. – No. 25. – R. 383–399.  
11.    Paton C., Barnes T.R., Cavanagh M.R. et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing // Br J Psychiatry. – 2008. – No. 192. – R. 435–439.
12.    Gallego J.A., Bonetti J., Zhang J., Kane J.M., Correll C.U. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009 // Schizophrenia Research. – 2012. – Vol. 138, No. 1. – R. 18–28.
13.    Aggarwal N.K., Sernyak M.J., Rosenheck R.A. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications // J Clin Psychopharmacol. – 2012. – No. 32. –R. 323–328.
14.    Jeon S-W. Kim Y-K. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: Antipsychotic polypharmacy and metabolic syndrome // Int J Mol Sci. –2017. – Vol. 18, No. 10. – R. 2174. –DOI: 10.3390/ijms18102174/
15.    Ijaz S., Bolea B., Davies S., Savović J., Richards A., Sullivan S., Moran P. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews // BMC Psychiatry. – 2018. – No. 18. – R. 275.
16.    Mosolov S.N., Tsukarzi E.E., Oleneva E.V., Alfimov P.V. Sovremennye metody preodoleniya terapevticheskoi rezistentnosti pri shizofrenii // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 102–117. 
17.    Tapp A., Wood A.E., Secrest L. et al. Combination antipsychotic therapy in clinical practice // Psychiatr Serv. – 2003. – No. 54. – R. 55–59.
18.    Kishimoto T., Watanabe K., Uchida H. et al. Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and rationales // Psychiatry Res. – 2013. – № 209. – R. 406–411.
19.    Lin C.H., Wang F.C., Lin S.C. et al. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study // Int Clin Psychopharmacol. – 2013. – No. 28. – R. 267–274.
20.    Malandain L., Thibaut F., Grimaldi-Bensouda L. et al. Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: Results from a nationwide cohort study // Schizophr Res. – 2018. – No. 192. – R. 213–218.
21.    Kadra G., Stewart R., Shetty H. et al. Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare // Schizophr Res. – 2016. – No. 174. – R. 106–112. 
22.    Hatta K., Hasegawa H., Imai A. et al. Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia // Asian J Psychiatr. – 2019. – No. 40. – R. 82–87. – DOI: 10.1016/j.ajp.2019.02.005
23.    Paton C., Whittington C., Barnes T.R. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis // J Clin Psychopharmacol. – 2007. – No. 27. – R. 198–204.  
24.    Correll C.U., Rummel-Kluge C., Corves C. et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials // Schizophr Bull. – 2009. – No. 35. – R. 443–457.  
25.    Barbui C., Signoretti A., Mule S. et al. Does the addition of a second antipsychotic drug improve clozapine treatment? // Schizophr Bull. – 2009. – No. 35. – R. 458–468.
26.    Barber S., Olotu U., Corsi M., Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia // Cochrane Database Syst Rev. – 2017. – No. 3. – Art. No.: CD006324. – DOI: 10.1002/14651858.CD006324.pub3
27.    Porcelli S., Balzarro B., Serretti A. Clozapine resistance: augmentation strategies // Eur Neuropsychopharmacol. – 2012. – Vol. 22, No. 3. – R. 165–182.
28.    Sommer I.E., Begemann M.J., Temmerman A., Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review // Schizophr Bull. – 2012. – No. 38. – R. 1003–1011. 
29.    Ortiz-Orendain J., Castiello-de Obeso S., Colunga-Lozano L.E. et al. Antipsychotic combinations for schizophrenia // Cochrane Database of Systematic Reviews. – 2017. – No. 6. – Art. No.: CD009005. – DOI: 10.1002/14651858.CD009005.pub2
30.    Baandrup L. Polypharmacy in schizophrenia // Basic Clin Pharmacol Toxicol. – 2020. – No. 126. – R. 183–192.
31.    Essock S.M., Schooler N.R., Stroup T.S. et al. Effectiveness of Switching from Antipsychotic Polypharmacy to Monotherapy // Am J Psychiatry. – 2011. – Vol. 168, No. 7. – R. 702–708. – DOI:  10.1176/appi.ajp.2011.10060908
32.    Constantine R.J., Andel R., McPherson M., Tandon R. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial // Schizophr Res. – 2015. – No. 166. – R. 194–200.
33.    Mace S., Taylor D. Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme // Ther Adv Psychopharmacol. – 2015. – No. 5. – R. 4–12. – DOI: 10.1177/2045124558055314
34.    Lin S.K. Antipsychotic Polypharmacy: A dirty little secret or a fashion? // Int J of Neuropsychopharmacology. – 2020. – Vol. 23, No. 2. – R. 125–131. – DOI: 10.1093/ijnp/pyz068
35.    Zink M., Englisch S., Meyer-Lindenberg A. Polypharmacy in schizophrenia // Curr Opin Psychiatry. – 2010. – Vol. 23, No. 2. – R. 103–111.
36.    Galling B., Roldan A., Hagi K. et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis // World Psychiatry. – 2017. – Vol. 16, No. 1. – R. 77–89.
37.    Uttaro T., Finnerty M., White T. et al. Reduction of concurrent antipsychotic prescribing practices through the use of PSYCKES // Adm Policy Ment Health. – 2007. – Vol. 34, No.1. – R. 57–61. – DOI: 10.1007/s10488-006-0075-x
38.    Petrova N.N., Ivanov M.V., Kosterin D.N. i dr. Kharakteristika remissii u bol'nykh shizofreniei na fone lecheniya antipsikhoticheskimi preparatami prolongirovannogo deistviya // Psikhiatriya i psikhofarmakoterapiya. – 2015. – T. 17, № 5. – S. 24–29.
39.    Netley J., Gaul J., Ferguson C. Evaluation of prescribing patterns of long-acting injectable antipsychotics within a community health system // Journal of Clinical Psychopharmacology. – 2019. – Vol. 39, No. 5. – R. 494–498. – DOI: 10.1097/JCP.0000000000001095
40.    Doshi J., Pettit A.R., Stoddard J. J. et al. Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge // J Clin Psychopharmacol. – 2015. – No. 35. – R. 442–446. – DOI: 10.1097/JCP.0000000000000353
41.    Koen L., Magni P., Niehaus D.J. et al. Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder // Afr J Psychiatry (Johannesbg). – 2008. – No. 11. – R. 287–290.
42.    Correll C.U., Shaikh L., Gallego J.A. et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior // Schizophrenia Research. – 2011. – Vol. 131, No. 1–3. – R. 58–62. – DOI: 10.1016/j.schres.2011.02.016
43.    Vermeir M., Naessens I., Remmerie B. et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans // Drug Metabolism and Disposition. – 2008. – Vol. 36, No. 4. – P. 769–779. – DOI: 10.1124/dmd.107.018275
44.    Devrimci-Ozguven H., Atmaca M., Baran Z. et al. Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia A Real-World Multicenter, Retrospective, Mirror-Image Study // J of Clin Psychopharmacology. – 2019. – Vol 39, No. 6. – P. 604–610.
45.    Stahl S.M. Antipsychotic polypharmacy: squandering precious resources? // J Clin Psychiatry. – 2002. – No. 63. – R. 93–94.
46.    Moore B.A., Morrissette D.A., Meyer J.M., Stahl S.M. Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing // Bjpsych Bull. – 2017. – No. 41. – R. 164–168.
47.    Stahl S.M. Antipsychotic polypharmacy: never say never, but never say always // Acta Psychiatr Scand. – 2012. – No. 125. – R. 349–351.